Sturlimogene Erparepvec

Phase 2Gene therapy

Sturlimogene Erparepvec is one of 2 biologic programs targeting Metastatic Renal Cell Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Renal Cell CancerNot yet recruiting

Metastatic Renal Cell CancerPhase 2

Not yet recruiting

Competition

Competitive Landscape

1 competitor in Metastatic Renal Cell Cancer

#DrugCompanyPhaseTrials

Fotivda

AAVEO Pharmaceuticals, Inc.

Phase 2

1 2

Sturlimogene Erparepvec

CCity of Hope Medical Center

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Not yet recruiting

Metastatic Renal Cell Cancer

NCT07218692

Clinical

Trials by Indication[1]

Metastatic Renal Cell Cancer1 trial

RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy

Not yet recruiting·—·Phase 2·NCT07218692·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sturlimogene Erparepvec. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sturlimogene Erparepvec compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sturlimogene Erparepvec. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — City of Hope Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Gene therapy[2]
Highest Phase: Phase 2[1]
Company: CCity of Hope Medical Center

Sturlimogene Erparepvec

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Metastatic Renal Cell Cancer1 trial

References

Drug Info

Quick Facts

Related News